ASCO
31 maja 2019
ASCO Annual Meeting 2019, May 31-June 4, Chicago, IL, USA
Rok
2019
Cel
daposertib (MEN1703 / SEL24), PIM/FLT3
Zasoby na tej stronie
Pobierz zasoby
- plik pdf
"CLI24-001: First-in-human study of SEL24/MEN1703, an oral dual PIM/FLT3 kinase inhibitor, in patients with acute myeloid leukemia"
Pobierz